Silk Road CEO Rogers Recalls Vital Lessons Learned
With over $100 million in capital raised from well-heeled investors including Warburg Pincus, the Vertical Group, Norwest Venture Partners, and the Janus Funds, Silk Road Medical is built for the long haul.
The company’s TransCarotid Artery Revascularization (TCAR) procedure promises to upend the treatment of blockages in the carotid artery by changing the direction blood flows through the critical artery, reducing the risk for debris to cause a stroke by reaching the brain.
Under the leadership of Medtech veteran Erica Rogers, Silk Road has secured strong support from clinical, regulatory, and reimbursement communities for its ENROUTE stenting and neuroprotection systems.
Now, the company is setting a clear course toward an IPO, an outcome that would be a welcome win for the Medtech sector.
In this Medtech Talk Podcast, Rogers recounts how she came to lead Silk Road Medical after overcoming her own initial reluctance to leave a post she loved at Medicines360, a non-profit pharmaceutical company.
She also gives an honest look back at her career including the outstanding successes of co-founding eye leader Visiogen and the painful, but educational experience leading a start-up sunk by disappointing clinical trials.
Rogers shares how a frank assessment of those successes and failures shaped the leadership style that has helped put Silk Road on a fast track to success.
Other topics she discusses:
- How did she get into the Medtech sector?
- How, as a co-founder of Visiogen, did she keep the faith when many experts rejected the concept?
- What lessons can be learned from failure?
- How did she help put Silk Road on course for success?
- What do investors like Norwest Venture Partners bring to the table other than capital?